APOBEC3B and breast cancer: Both A3A and A3A_B were found to exhibit stronger cytidine deaminase activity than A3B in an in vitro study21, and breast cancer patients harboring A3B deletions were found to have more APOBEC-dependent mutations than patients lacking an A3B deletion22.